AMAÇBu çalışmada, antioksidan özelliği bilinen glutaminin kullanımının iskemi-reperfüzyon sonrası oluşabilecek oksidasyon hasarı üzerindeki etkilerini araştırmayı amaçladık. GEREÇ VE YÖNTEMÇalışma grubu Wistar Albino sıçanlarla oluşturuldu. Grup 1, abdominal kompartman grubuydu. Anestezi altındaki sı-çanların karnına basınç uygulandı. Gaz boşaltıldıktan 3 gün sonra sıçanlar sakrifiye edildi, karaciğer, bağırsak ve akciğer doku parçalarında oksidatif hasar parametresi olarak malonildialdehit (MDA) ve glutatyon (GSH) seviyeleri ile enflamatuvar parametre olarak miyeloperoksidaz (MPO) aktivitesi ölçüldü. Alınan kan örneklerinde serum alaninaminoasit transferaz (ALT) ve aspartat-aminoasit transferaz (AST) seviyeleri ölçüldü. Grup 2, abdominal kompartman ve glutamin uygulanan gruptu. Sıçanlara 1 hafta boyunca yüksek doz glutamin mide gavajı yolu ile verildi. Gavaj işlemi sonrası ilk gruptaki batın içi basınç uygulaması yapıldı, 3 gün daha glutamin verilen sıçanlar sakrifiye edildi, Grup 1'deki işlemlerin aynısı yapıldı. Grup 3 glutamin grubuydu. Grup 4 sham kontrol grubuydu. BULGULARAbdominal kompartman yaratılan sıçanlarda MDA düzeyi ve MPO aktivitesi kontrol grubuna göre anlamlı oranda artmıştı. Glutamin ile MDA düzeyi ve MPO aktivitesi azaldı, GSH seviyesi arttı. SONUÇOksidatif hasar parametrelerine bakıldığında, glutaminin, reperfüzyon hasarını azaltıcı etkisinin antienflamatuvar ve antioksidan etkilerine bağlı olduğu düşünülmüştür.

We aimed to investigate whether or not cardiotrophin-1 (CT-1) can be used as a predictor of sinus rhythm constancy in patients with atrial fibrillation (AF) converted to sinus rhythm. Thirty two patients with AF (48-78 years), without any structural heart disease were enrolled for the study. The control group consisted of 32, age and gender matched healthy persons. Measurements of CT-1 were made after transthoracic and transesophageal echocardiography prior to cardioversion (CV). Relapses of AF were investigated by monthly electrocardiograms (ECGs) and ambulatory ECGs at 1 st , 3 rd , and 6 th month. At the end of 6th month, measurements of CT-1 were repeated. At the beginning patients with AF had increased CT-1 levels when compared to controls (0.94 ± 0.32 pg/mL vs. 0.30 ± 0.12 pg/mL, [p < 0.001]). At the end of follow-up of the 32 patients, 17 (53%) had AF relapse. Age, initial duration of AF, left ventricle diameters, ejection fraction, left atrium appendix flow rates were similar among patients with and without AF relapse. However, basal left atrium diameter (4.24 ± 0.14 cm vs. 4.04 ± 0.22 cm, p = 0.005), pulmonary artery pressure (32.82 ± 5 vs. 28.60 ± 6.23 mmHg, p = 0.004) and CT-1 values (1.08 ± 0.37 vs. 0.82 ± 0.16 pg/mL, p = 0.02) were significantly increased in patients with AF relapse. Furthermore, patients with relapsed AF had higher CT-1 levels at 6 th month when compared to those in sinus rhythm (1.00 ± 0.40 vs. 0.71 ± 0.23 pg/mL). We conclude that post-CV, AF relapses are more frequent among patients with increased baseline CT-1 levels, and CT-1 may be a potential predictor of AF relapse.

Background/Aims: Congenital adrenal hyperplasia (CAH) is characterized by adrenal insufficiency with or without salt wasting. It is also accompanied by adrenomedullary hypofunction. The aim of the present study was to investigate adrenomedullary function in patients with CAH due to 21-hydroxylase and 11β-hydroxylase deficiencies and in age-matched normal subjects. Methods: We measured plasma catecholamines (epinephrine and norepinephrine) and urine metanephrine in 44 patients with CAH, 32 due to 21-hydroxylase deficiency (17 patients with the salt-wasting form and 15 patients with the simple virilizing form), and 12 due to 11β-hydroxylase deficiency, and in 25 healthy controls. Results: Plasma epinephrine and urine metanephrine levels were significantly higher in the controls than in patients with CAH (p = 0.02 and p < 0.001, respectively). Plasma norepinephrine levels were significantly lower in the controls than in patients with CAH (p < 0.001). Interestingly, patients with the salt-wasting form had lower norepinephrine levels in comparison to the other subgroups of CAH. Conclusion: Despite the fact that CAH patients have insufficient epinephrine secretion, these patients have the ability to increase compensatory norepinephrine. However, this increase is much lower in patients with the salt-wasting form. These findings need to be confirmed by other studies.

The DNA damage scores were significantly inversely correlated with FMD measures. To our knowledge, this is the first study showing the presence of a relation between DNA damage scores and FMD.

No abstract